Cargando…

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties

SIMPLE SUMMARY: Glycogen synthase kinase-3 beta is a protein kinase implicated in the promotion and development of various cancers, including pancreatic cancer. In cell culture and animal studies, drugs targeting the inhibition of this protein show treatment potential in pancreatic cancer. Studies s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Robin, Coveler, Andrew L., Cavalcante, Ludimila, Saeed, Anwaar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301062/ https://www.ncbi.nlm.nih.gov/pubmed/34356465 http://dx.doi.org/10.3390/biology10070610

Ejemplares similares

SLAM Modification as an Immune-Modulatory Therapeutic Approach in Cancer
por: Tojjari, Alireza, et al.
Publicado: (2023)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
por: Odia, Yazmin, et al.
Publicado: (2022)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019)

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)

Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
por: Coats, Josh T., et al.
Publicado: (2023)

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020)

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()
por: Ugolkov, Andrey, et al.
Publicado: (2017)

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells
por: Shaw, Gary, et al.
Publicado: (2022)

Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
por: Jeffers, Ann, et al.
Publicado: (2019)

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
por: Karmali, Reem, et al.
Publicado: (2017)

Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
por: Atri-Schuller, Aviva, et al.
Publicado: (2022)

Focusing the spotlight on GSK-3 in aging
por: Zhou, Jibin, et al.
Publicado: (2013)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
por: Tojjari, Alireza, et al.
Publicado: (2023)

A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
por: Tojjari, Alireza, et al.
Publicado: (2023)

Different expression of GSK3β and pS9GSK3β depending on phenotype of cervical cancer: possible association of GSK3β with squamous cell carcinoma and pS9GSK3β with adenocarcinoma
por: Ahn, Kwanghee, et al.
Publicado: (2019)

Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
por: Liu, Qingjun, et al.
Publicado: (2011)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Archibald Inglis
Publicado: (1889)

Mallet-ing
Publicado: (1860)

Inge Borghuis
por: Kiers, Bart
Publicado: (2020)

“HASH”ing out pancreatitis: the new increasingly common culprit
por: Chandy, Joel, et al.
Publicado: (2019)

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
por: Priantti, Jonathan N., et al.
Publicado: (2023)

Inge J. Lissajoux
Publicado: (2016)

Orbit(ing) the furrow
por: Sreenivasan, Aparna
Publicado: (2004)

SNP'ing for longevity
por: Vijg, Jan
Publicado: (2009)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

Elsie Maud Inglis
por: Russell, Beatrice
Publicado: (1918)

David Wood Inglis
Publicado: (1934)

Professor Inglis of Aberdeen
Publicado: (1875)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
por: Chiorean, Elena Gabriela, et al.
Publicado: (2015)

FRET-ing over scaffolds
por: LeBrasseur, Nicole
Publicado: (2003)

Gett(er)ing to nothing
por: Benvenuti, Cristoforo
Publicado: (2004)

Spy'ing on differentiation in neuroblastoma
por: Podkowa, Monika, et al.
Publicado: (2014)

STIR(ing) appearance of rhabdomyolysis
por: Chakera, Aron, et al.
Publicado: (2008)

Captain Robert Inglis Binning
Publicado: (1916)

"T-bet"-ing on autoimmunity variants
por: Nguyen, Michelle L. T., et al.
Publicado: (2017)

Biological Functions of the ING Proteins
por: Dantas, Arthur, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rkinv4e4ifp3dfq5o4ed1dppl3